Study Reveals High Pregnancy Risks for Lupus Patients Not in Remission
Research indicates that women with systemic lupus erythematosus face significant pregnancy complications if not in remission.
82% of higher-risk lupus patients experienced adverse pregnancy outcomes.
Pregnancy complications are more common in women not in remission.
Broader definitions reveal a higher burden of complications.
A recent study has highlighted the increased risk of adverse pregnancy outcomes for women with systemic lupus erythematosus (SLE) who are not in remission. Conducted as a prospective cohort study, the research evaluated pregnancy complications across various severity groups, revealing that complications can affect up to 82% of higher-risk patients. The findings underscore the critical importance of achieving disease remission prior to pregnancy, especially for women with additional clinical risk factors.
Historically, SLE has been linked to various pregnancy complications, including preterm birth, pre-eclampsia, and pregnancy loss. Previous studies, notably the PROMISSE study, have set benchmarks for pregnancy outcomes in women with SLE. However, PROMISSE's exclusion of certain high-risk patients and its narrow definitions of complications may have led to an underestimation of the true burden faced by the broader SLE population.
In this latest study, researchers assessed 107 pregnancies among individuals with SLE, focusing on both PROMISSE eligibility criteria and a subgroup of higher-risk patients. The results indicated that adverse pregnancy outcomes occurred in 30% of the overall cohort when using PROMISSE definitions. However, the rate of complications was significantly higher in the higher-risk group, with 59% affected, compared to 24% of PROMISSE-eligible patients. When broader criteria from the American College of Obstetricians and Gynecologists (ACOG) were applied, the overall complication rate rose to 50%.
The implications of these findings are substantial for women with SLE and the healthcare providers who support them. The study suggests that the high rates of complications among PROMISSE-ineligible patients reflect a population that may need to defer pregnancy until their disease is better controlled. Additionally, the research emphasizes the need for individualized preconception counseling, particularly for those with active disease or other risk factors.
Looking ahead, the researchers advocate for a more nuanced approach to assessing pregnancy risks in women with SLE. They recommend evaluating disease activity and remission status before pregnancy to provide better-informed risk estimates. While the study does not establish a direct causal relationship between remission and reduced pregnancy complications, it reinforces the importance of disease management in planning for pregnancy.
